A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.

CONCLUSION: Apatinib monotherapy showed promising efficiency for patients with refractory colorectal cancer, especially in patients with PS 0-1 or no liver metastasis. ctDNA abundance may be a predictor in serial monitoring of tumor load.
PMID: 30877190 [PubMed - as supplied by publisher]

Source: The Oncologist - March 14, 2019 Category: Cancer & Oncology Authors: Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, Shu Y, Chang L, Jiang H, Gu Y Tags: Oncologist Source Type: research